- Home
- NIO vs ROIV Comparison
NIO vs ROIV Comparison
Compare NIO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIO
- ROIV
- Stock Information
- Founded
- NIO 2014
- ROIV 2014
- Country
- NIO China
- ROIV United Kingdom
- Employees
- NIO N/A
- ROIV N/A
- Industry
- NIO Auto Manufacturing
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- NIO Consumer Discretionary
- ROIV Health Care
- Exchange
- NIO Nasdaq
- ROIV Nasdaq
- Market Cap
- NIO 7.4B
- ROIV 8.4B
- IPO Year
- NIO 2018
- ROIV N/A
- Fundamental
- Price
- NIO $4.20
- ROIV $10.99
- Analyst Decision
- NIO Hold
- ROIV Buy
- Analyst Count
- NIO 6
- ROIV 4
- Target Price
- NIO $5.05
- ROIV $17.50
- AVG Volume (30 Days)
- NIO 37.0M
- ROIV 6.4M
- Earning Date
- NIO 06-05-2025
- ROIV 05-29-2025
- Dividend Yield
- NIO N/A
- ROIV N/A
- EPS Growth
- NIO N/A
- ROIV N/A
- EPS
- NIO N/A
- ROIV N/A
- Revenue
- NIO $9,005,433,398.00
- ROIV $122,585,000.00
- Revenue This Year
- NIO $37.33
- ROIV N/A
- Revenue Next Year
- NIO $25.67
- ROIV N/A
- P/E Ratio
- NIO N/A
- ROIV N/A
- Revenue Growth
- NIO 18.18
- ROIV 140.04
- 52 Week Low
- NIO $3.02
- ROIV $8.73
- 52 Week High
- NIO $7.71
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- NIO 56.91
- ROIV 51.57
- Support Level
- NIO $3.82
- ROIV $11.02
- Resistance Level
- NIO $4.15
- ROIV $11.77
- Average True Range (ATR)
- NIO 0.16
- ROIV 0.34
- MACD
- NIO 0.03
- ROIV -0.04
- Stochastic Oscillator
- NIO 58.87
- ROIV 25.52
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.